1. Edelson Lechtzin LLP is investigating OM for misleading information. 2. OM reported Q3 2025 results missing consensus estimates. 3. Stock price dropped 48.47% post-earnings announcement. 4. Revenue guidance for 2025 was lowered significantly. 5. Investors may pursue legal action for substantial losses.
The missed earnings and drastic stock price drop indicate financial instability. Historical examples show similar investigations led to long-term declines in affected companies.
The article discusses a significant legal investigation that could affect stock prices. Investors and analysts will scrutinize OM closely in light of these allegations.
The immediate concern relates to ongoing investigations that could further erode investor confidence. Past price recoveries often take significant time, but initial reactions are pronounced.
NEWTOWN, Pa., Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Outset Medical, Inc. (NASDAQ:OM), resulting from allegations of providing potentially misleading business information to the investing public.
If you have non-public information that could assist in the Outset Medical Investigation or if you are an Outset Medical investor who suffered a loss and would like to learn more, you can provide your information HERE.
You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 ext. 1, or via e-mail at elechtzin@edelson-law.com.
THE COMPANY:
Outset Medical Inc., based in San Jose, California, is a medical technology company that develops and produces the Tablo Hemodialysis System.
THE ALLEGED WRONGDOING:
On November 10, 2025, Outset Medical announced its third-quarter 2025 financial results, reporting non-GAAP earnings per share of –$0.69, missing consensus estimates by $0.03, and revenue of $29.43 million, falling short of expectations by $1.27 million.
The Company also lowered its full-year 2025 revenue guidance to $115–$120 million from its prior range of $122–$126 million, citing delays in the timing of several large, anticipated opportunities.
Following the announcement, the price of Outset Medical stock fell $5.85 per share, or 48.47%, to close at $6.22 per share on November 11, 2025.
ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.
For more information, please contact:
Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: medelson@edelson-law.com
Email: elechtzin@edelson-law.com
Web: www.edelson-law.com
This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-edelson-lechtzin-llp-announces-investigation-of-outset-medical-inc-nasdaq-om-and-encourages-investors-with-substantial-losses-to-contact-the-firm-302628297.html
SOURCE Edelson Lechtzin LLP